Table 1.
Currently active or completed clinical trials utilizing replication-competent viruses against malignant gliomas. Search results from clinicaltrials.gov.
| Currently Active or Recruiting | |||||
| Adenovirus | Virus Construct | Phase | Therapy Regimen | Trial No. | Results |
| DNX-2401 + pembrolizumab | Deletion in E1A. RGD-4C fiber modification | II | IT injection followed by Pembrolizumab (IV) every 3 weeks | NCT02798406 | - |
| DNX-2440 | DNX-2401 (above) armed with OX40L | I | IT injection | NCT03714334 | - |
| CRad-S-pk7 (loaded into neural stem cells) | E1A under survivin promoter, pK7 fiber modification | I | injection into resection cavity | NCT03072134 | - |
| HSV | Virus Construct | Phase | Therapy Regimen | Trial No. | Results |
| C134 | γ34.5 deletion IRS1 under HCMV promoter |
I | IT injection | NCT03657576 | - |
| M032 | γ34.5 deletion Armed with human IL-12 |
I | single IT infusion | NCT02062827NSC733972 | - |
| rQNestin 34.5 | One copy of γ34.5 under nestin promoter With UL39 deletion |
I | IT with/without preceding IV cyclophosphamide | NCT03152318 | - |
| G207 | γ34.5 deletion Inactivating insertion of lacZ in UL39 gene | I | IT infusion | NCT02457845 | - |
| Other | Virus Construct | Phase | Therapy Regimen | Trial No. | Results |
| Vaccinia virus TG6002 + 5-FC | TK and RR deletion Expresses cytosine deaminase |
I/II | 3 weekly IV infusions, followed by oral 5-FC | NCT03294486 | - |
| Measles Virus (MV-CEA) | expresses CEA | I | injection into resection cavity and/or IT | NCT00390299 | - |
| Poliovirus (PVSRIPO) | attenuated (Sabin) poliovirus with IRES from HRV2 | I/Ib | IT via convection- enhanced delivery | NCT01491893NCT03043391 | [20] |
| Reovirus (REOLYSIN) + sargramostim (rGM-CSF) | unmodified reovirus | I | repeated cycles of sargamostim followed by IV virus | NCT02444546 | - |
| Toca 511 + Toca FC | described above | II/III | injection into resection cavity followed by oral Toca FC |
NCT02414165 | - |
| Completed | |||||
| Adenovirus | Virus Construct | Phase | Therapy Regimen | Trial No. | Results |
| DNX-2401 + Temozolomide | described above | I | injection in the brain parenchyma followed by temozolomide | NCT01956734 | - |
| DNX-2401 + IFNγ | described above | I | IT injection followed by IFNγ | NCT02197169 | - |
| DNX-2401 | described above | I/II | intracerebral infusion | NCT01582516 | [21] |
| Other | Virus Construct | Phase | Therapy Regimen | Trial No. | Results |
| HSV G207 | described above | I/II | IT injection | NCT00028158 | [31] |
| Parvovirus H-1PV | unmodified rat parvovirus | I/II | combinations of IV, IT, and resection cavity injections | NCT01301430 | [32] |
| Reovirus (REOLYSIN) | unmodified human reovirus | I | IT infusion | NCT00528684 | [33] |
| Toca 511 + Toca FC | described above | I | injection in resection cavity followed by oral Toca FC | NCT01470794 | [22,34] |
Abbreviations: IT: intratumoral, IV: intravenous, HSV: herpes simplex virus, HCMV: human cytomegalovirus, IL-12: interleukin 12, TK: thymidine kinase gene, RR: ribonucleotide reductase gene, 5-FC: 5-fluorocytosine, CEA: carcinoembryonic antigen, IRES: internal ribosomal entry site, HRV2: human rhinovirus 2, rGM-CSF: recombinant granulocyte-macrophage colony-stimulating factor, IFN-γ: interferon gamma.